Publication:
Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors

dc.contributor.authorDesmond Y.H. Yapen_US
dc.contributor.authorLawrence P. McMahonen_US
dc.contributor.authorChuan Ming Haoen_US
dc.contributor.authorNan Huen_US
dc.contributor.authorHirokazu Okadaen_US
dc.contributor.authorYusuke Suzukien_US
dc.contributor.authorSung Gyun Kimen_US
dc.contributor.authorSoo Kun Limen_US
dc.contributor.authorKriengsak Vareesangthipen_US
dc.contributor.authorChi Chih Hungen_US
dc.contributor.authorMasaomi Nangakuen_US
dc.contributor.otherGraduate School of Medicineen_US
dc.contributor.otherPeking University First Hospitalen_US
dc.contributor.otherKaohsiung Medical University Chung-Ho Memorial Hospitalen_US
dc.contributor.otherSaitama Medical Universityen_US
dc.contributor.otherHallym Universityen_US
dc.contributor.otherUniversity of Malaya Medical Centreen_US
dc.contributor.otherFaculty of Medicine, Nursing and Health Sciencesen_US
dc.contributor.otherFaculty of Medicine Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherFudan Universityen_US
dc.contributor.otherJuntendo University School of Medicineen_US
dc.contributor.otherThe University of Hong Kongen_US
dc.date.accessioned2022-08-04T11:02:09Z
dc.date.available2022-08-04T11:02:09Z
dc.date.issued2021-02-01en_US
dc.description.abstractRenal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard-of-care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF-prolyl hydroxylase inhibitors (HIF-PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia-Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF-PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia-Pacific region who have clinical experience or have been investigators in HIF-PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF-PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF-PHI, taking into account both available data and expert opinion in areas where evidence remains scarce.en_US
dc.identifier.citationNephrology. Vol.26, No.2 (2021), 105-118en_US
dc.identifier.doi10.1111/nep.13835en_US
dc.identifier.issn14401797en_US
dc.identifier.issn13205358en_US
dc.identifier.other2-s2.0-85097306486en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/78495
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097306486&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleRecommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitorsen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097306486&origin=inwarden_US

Files

Collections